Company selling CBD product penalized for COVID-19 prevention claims
The U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) is continuing to issue warning letters to companies for selling fraudulent novel coronavirus (COVID-19) products, as part of ongoing effort to protect consumers.
The agencies announced Wednesday that they issued a warning letter to Neuro XPF, which sells cannabidiol (CBD) products in the U.S., with the misleading claim these products can mitigate, prevent, treat, diagnose, or cure COVID-19.
According to the published warning letter, the company claimed on its website that its products would “help keep your immune system at the top of its game,” and “prepare your body to fight a coronavirus infection.”
The company has 48 hours to respond to the FDA’s COVID-19 Task Force with steps they will take to correct the violations.
The FDA and FTC said they are continuing to monitor social media in particular and pursue companies that they deem put public health at risk.
Editor’s note: Click here for more information and ongoing COVID-19 updates for integrative healthcare professionals.